Abstract
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.
Copyright 2000 S. Karger AG, Basel
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Age Factors
-
Aged
-
Alzheimer Disease / diagnosis
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / physiopathology
-
Carbamates / administration & dosage*
-
Carbamates / adverse effects
-
Cholinesterase Inhibitors / administration & dosage*
-
Cholinesterase Inhibitors / adverse effects
-
Cognition / drug effects
-
Cognition / physiology
-
Disease Progression
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Humans
-
Phenylcarbamates*
-
Rivastigmine
-
Time Factors
-
Treatment Outcome
Substances
-
Carbamates
-
Cholinesterase Inhibitors
-
Phenylcarbamates
-
Rivastigmine